newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara delivers significant operational efficiencies and extends cash runway through year-end 2026 A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA Atara Biotherapeutics, Inc.